Novo Nordisk Ends Lawsuit, Collaborates With Hims & Hers to Sell Semaglutide
(MedPage Today) — Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see branded semaglutide (Ozempic, Wegovy) products sold through the…
AbbVie’s Amylin Candidate ‘Competitive’ in Early-Stage Trial
AbbVie’s foray into the obesity space is successful so far, analysts agree, as amylin analog ABBV-295 elicited as much as 9.73% weight loss at 13 weeks in the multiple ascending dose portion of a Phase 1 trial.
Novo Nordisk Agrees To Sell GLP-1 Drugs Via Hims & Hers, Ending Dispute
The companies have been embroiled in a row about compounded GLP-1 drugs that escalated to a lawsuit last month. The legal action has now been dropped and the former adversaries have struck a deal that could increase access to Novo’s obesity medicines.
GLP-1 Drugs and Bone Injury; ‘Fire-Breathing’ Teen Trend; Saunas’ Health Benefits?
(MedPage Today) — Note that some links may require registration or subscription.
GLP-1 receptor agonists may increase the risk of bone and tendon injuries along with conditions such as osteoporosis and gout, a retrospective study suggested. …
STAT+: Novo Nordisk, Hims reach deal to end bitter dispute over Wegovy sales
Novo Nordisk and Hims & Hers have reached a deal that, for now, appears to end their bitter dispute around Hims’ sale of compounded versions of Novo’s blockbuster obesity drug…
GLP-1 drugs linked to higher fracture risk, osteoporosis and gout, new studies suggest
New study suggests GLP-1 drugs like Ozempic and Wegovy may raise fracture risk by 11% in adults 65 and older with type 2 diabetes compared to other diabetes medications.
Could GLP-1 drugs cut the risk of complications after a heart attack?
How do GLP-1 agonists affect gene expression?
GLP-1s are building a reputation as “wonder drugs.” First characterized for their ability to improve insulin release and treat diabetes, the drugs were later found to promote weight loss and improve cardiovascular health. In addition to these surprising bonus benefits is the ability of GLP-1 drugs to improve pancreatic beta cell health. But how, exactly, are they doing that?
STAT+: Novo Nordisk’s Wegovy and Ozempic shots could be made for as little as $3 a month, analysis finds
Generic versions of Novo Nordisk’s Wegovy and Ozempic medications could be mass produced for about $3 per person a month, according to a new analysis.
Zealand touts efficacy, safety for petrelintide phase II obesity trial
Investors looking for midteen percentage weight loss findings in Zealand Pharma A/S’s phase II study of once-weekly amylin analogue petrelintide were clearly disappointed by the actual 10.7% mean body weight reduction, as shares (Copenhagen:ZEAL) fell 36% March 6. But from the company’s standpoint, the combination of efficacy and safety data from the Zupreme-1 study bode well for a phase III trial expected to start later this year.